Clinical decision making and the expected value of information

Clinical Trials

Volumn 4, Issue 3, 2007, Pages 279-285

  Willan, Andrew R ^a  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RAMIPRIL;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; CLINICAL STUDY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; HEART INFARCTION; HUMAN; MEDICAL INFORMATION; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; STROKE; SYSTEMATIC REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DECISION MAKING; HUMANS; MIDDLE AGED; RAMIPRIL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAMPLE SIZE;

EID: 34548602954     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774507079237     Document Type: Article

References (20)

1. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular dvents in high-risk patients. N Engl J Med 2000; 342: 145-53.
2. Lamy A, Yusuf S, Pogue J, Gafni A. Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003; 106: 960-65.
3. Hornberger JC, Brown Jr BW, Halpern J. Designing a cost-effective clinical trial. Statistics in Medicine 1995; 14: 2249-59.
4. Claxton K, Posnett J. An economic approach to clinical trial design and research priority setting. Health Economics 1996; 5: 513-24.
5. Gittins J. Quantitative methods in the planning of pharmaceutical research. Drug Information Journal 1996; 30: 479-87.
6. Lindley DV. The choice of sample size. The Statistician 1997; 46: 129-38.
7. Hornberger J, Eghtesady P. The cost-benefit of a randomized trial to a health care organization. Controlled Clinical Trials 1998; 19: 198-211.
8. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. Journal of Health Economics 1999; 18: 341-64.
9. Gittins J, Pezeshk H. How large should a trial be? The Statistician 2000; 49: 177-97.
10. Gittins J, Pezeshk H. A behavioral Bayes method for determining the size of a clinical trial. Drug Information Journal 2000; 34: 355-63.
11. Claxton K, Thompson KM. A dynamic programming approach to the efficient design of clinical trials. Journal of Health Economics 2001; 20: 797-822.
12. O'Hagan A, Stevens JW. Bayesian assessment of sample size for clinical trials of cost effectiveness. Medical Decision Making 2001; 21: 219-30.
13. Halpern J, Brown Jr BW, Hornberger J. The sample size for a clinical trial: a Bayesian-decision theoretic approach. Stat Med 2001; 20: 841-58.
14. Pezeshk H, Gittins J. A fully Bayesian approach to calculating sample sizes for clinical trials with binary response. Drug Information Journal 2002; 36: 143-50.
15. Pezeshk H. Bayesian techniques for sample size determination in clinical trials: a short review. Statistical Methodology in Medical Research 2003; 12: 489-504.
16. Willan AR, Pinto EM. The expected value of information and optimal clinical trial design. Stat Med 2005; 24: 1791-806. Correction: Stat Med 2006; 25: 720.
17. Grundy PM, Healy MJR, Rees DH. Economic choice of the amount of experimentation. Journal of the Royal Statistical Society, Series A 1956; 18: 32-48.
18. Raiffa H, Schlaifer R. Applied statistical decision theory. John Wiley and Sons, 2000.
19. Willan AR, Cruess AF, Ballantyne M. Argon green vs krypton red laser photocoagulation of extrafoveal choroidal neovascular lesions: Three-year results in age-related macular degeneration. Canadian Journal of Ophthalmology 1996; 31: 11-17.
20. Hannah ME, Hannah WJ, Hewson SH, Hodnett ED, Saigal S, Willan AR. Term Breech Trial: a multicentre international randomised controlled trial of planned caesarean section and planned vaginal birth for breech presentation at term. The Lancet 2000; 356: 1375-83.